- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06694740
Efeito do interferon gama como tratamento para imunossupressão pós-agressiva em unidades de terapia intensiva, um ensaio bayesiano duplo-cego controlado versus placebo (INFINITY)
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).
We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.
Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Charles De ROQUETAILLADE, MD
- Número de telefone: +33 01 49 95 55 68
- E-mail: charles.de-roquetaillade@aphp.fr
Estude backup de contato
- Nome: Benjamin CHOUSTERMAN, Professor
- Número de telefone: +33 01 49 95 85 18
- E-mail: benjamin.chousterman@aphp.fr
Locais de estudo
-
-
-
Limoges, França, 87000
- Recrutamento
- Dr Francois Bruno
-
Contato:
- Bruno Francois, MD
- Número de telefone: +33 05 55 05 88 41
- E-mail: bruno.françois@chu-limoges.fr
-
Nancy, França
- Recrutamento
- Pr Antoine Kimmoun
-
Contato:
- Antoine Kimmoun, Professor
- Número de telefone: +33 03 83 85 14 95
- E-mail: a.kimmoun@chru-nancy.fr
-
Paris, França
- Recrutamento
- Pr Dépret
-
Contato:
- Pr Dépret François, Professor
- Número de telefone: +33 01 42 49 95 70
- E-mail: francois.depret@aphp.fr
-
Paris, França, 75010
- Recrutamento
- Pr Benjamin Chousterman
-
Contato:
- Chousterman Benjamin, Professor
- Número de telefone: +33 0149958518
- E-mail: benjamin.chousterman@aphp.fr
-
Paris, França, 75013
- Recrutamento
- Pr Constantin Michel
-
Contato:
- Michel Constantin, Professor
- Número de telefone: +33 01 42 16 22 59
- E-mail: Jean-michel.constantin@aphp.fr
-
Paris, França
- Recrutamento
- Pr Megarbane
-
Contato:
- Bruno Megarbane, Professor
- Número de telefone: +33 01 49 95 84 42
- E-mail: Bruno.megarbane@aphp.fr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patient ≥ 18 years old
- SOFA score for first 24 hours post-admission ≥ 6
- Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
- mHLA-DR< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
- Patient affiliated to a social security scheme
- Written informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible
Exclusion Criteria:
- Patient with estimated life expectancy of less than 3 months
- Patients with a predicted remaining stay in intensive care < 72 hours
- Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score < 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
- Pregnant or breast-feeding women
- Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
- Patients on immunosuppressive therapy, including long-term corticosteroid therapy (>2.5mg/d prednisone equivalent)
- Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
- Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
- People under court protection and protected adults
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: interferon gamma-1b injection
Patients randomized to the experimental arm will receive : Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
|
|
Comparador de Placebo: Placebo injection
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
number of days alive without mechanical ventilation
Prazo: on Day 28 after drug administration
|
number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day |
on Day 28 after drug administration
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
Prazo: Day 1 to Day 7 and at Day 28 post randomization
|
Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo. |
Day 1 to Day 7 and at Day 28 post randomization
|
|
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
Prazo: Day 0, Day 3 and at Day 7 post randomization
|
Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0, Day 3 and at Day 7 post randomization
|
|
mortality at Day 28 and Day 90 after randomization
Prazo: Day 28 and Day 90 after randomization
|
Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 and Day 90 after randomization
|
|
incidence of nosocomial infections during intensive care unit stay
Prazo: from Day 0 to Day 28 (or the discharge from intensive care)
|
The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
number of days alive whithout antibiotic
Prazo: Day 28 after drug administration
|
Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 after drug administration
|
|
length of stay in intensive care between patients
Prazo: from Day 0 to Day 28 (or the discharge from intensive care)
|
Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
Prazo: From inclusion to Day 7
|
Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo |
From inclusion to Day 7
|
|
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
Prazo: Day 0, Day 3 and Day 7 after randomization
|
Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier. |
Day 0, Day 3 and Day 7 after randomization
|
|
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo
Prazo: Day 0 to Day 7 and at Day 28 post randomization
|
Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0 to Day 7 and at Day 28 post randomization
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Benjamin Chousterman, Professor, APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Infecções
- Síndrome da Resposta Inflamatória Sistêmica
- Inflamação
- Condições Patológicas, Sinais e Sintomas
- Sepse
- Peptídeos
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Fatores biológicos
- Peptídeos e proteínas de sinalização intercelular
- Citocinas
- Interferons
- Linfocinas
- Fatores ativadores de macrófagos
- Interferon-gama
Outros números de identificação do estudo
- APHP220672
- 2023-506725-11-00 (Ctis)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .